GSK Hands Off Rare Disease Gene Therapy Portfolio to Orchard Therapeutics

GlaxoSmithKline (GSK) said today it will hand off its rare disease gene therapy portfolio — including its European-approved gene therapy Strimvelis™ — to two-year-old startup Orchard Therapeutics in return for taking a 19.9% stake in the acquirer, as well as undisclosed milestone payments and royalties, and a seat on Orchard’s board. Orchard Therapeutics is a portfolio company of 4BIO Capital.

Read more at GEN.